About Reunion Neuroscience
Reunion Neuroscience is a company based in Toronto (Canada) founded in 2022 was acquired by MPM Capital in June 2023.. Reunion Neuroscience has raised $103 million across 1 funding round from investors including Novo Holdings, Arkin Holdings and Mitsui Global Investment. Reunion Neuroscience offers products and services including RE104 and RE200s. Reunion Neuroscience operates in a competitive market with competitors including Alto Neuroscience, Supernus Pharmaceuticals, Newron Pharmaceuticals, Cerecor and Neurovance, among others.
- Headquarter Toronto, Canada
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Reunion Neuroscience Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$103 M (USD)
in 1 rounds
-
Latest Funding Round
$103 M (USD), Series A
Jan 12, 2024
-
Investors
Novo Holdings
& 7 more
-
Employee Count
Employee Count
-
Acquired by
MPM Capital
(Jun 01, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Reunion Neuroscience
Reunion Neuroscience offers a comprehensive portfolio of products and services, including RE104 and RE200s. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Prodrug targeting serotonin receptors for treating mental health disorders.
Psilocybin-like compound for fast-acting mental health therapies.
Unlock access to complete
Funding Insights of Reunion Neuroscience
Reunion Neuroscience has successfully raised a total of $103M through 1 strategic funding round. The most recent funding activity was a Series A round of $103 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $103.0M
-
First Round
First Round
(12 Jan 2024)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2024 | Amount | Series A - Reunion Neuroscience | Valuation | Novo Holdings , MPM BioImpact |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Reunion Neuroscience
Reunion Neuroscience has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Novo Holdings, Arkin Holdings and Mitsui Global Investment. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Corporate-backed venture capital firm focused on healthcare, IT, and multiple sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Reunion Neuroscience
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Reunion Neuroscience
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Reunion Neuroscience Comparisons
Competitors of Reunion Neuroscience
Reunion Neuroscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alto Neuroscience, Supernus Pharmaceuticals, Newron Pharmaceuticals, Cerecor and Neurovance, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers
|
|
| domain | founded_year | HQ Location |
Specialty pharmaceutical products for CNS diseases are developed and commercialized.
|
|
| domain | founded_year | HQ Location |
Therapies for central nervous system diseases and pain are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for immunological and neurological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Neurochemical modulators for ADHD treatment are developed by Neurovance.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Reunion Neuroscience
Frequently Asked Questions about Reunion Neuroscience
When was Reunion Neuroscience founded?
Reunion Neuroscience was founded in 2022 and raised its 1st funding round 2 years after it was founded.
Where is Reunion Neuroscience located?
Reunion Neuroscience is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Who is the current CEO of Reunion Neuroscience?
Greg Mayes is the current CEO of Reunion Neuroscience.
Is Reunion Neuroscience a funded company?
Reunion Neuroscience is a funded company, having raised a total of $103M across 1 funding round to date. The company's 1st funding round was a Series A of $103M, raised on Jan 12, 2024.
What does Reunion Neuroscience do?
Reunion Neuroscience was founded in 2022 in Toronto, Canada, within the biotechnology sector. Focus is placed on creating treatments for mental health disorders, including treatment-resistant depression and postpartum depression. The lead candidate, RE-104, is formulated as a serotonin-2A agonist prodrug. Additional efforts involve the RE-200 series of selective serotonergic psychedelic compounds. Operations center on research and development of these therapeutic options.
Who are the top competitors of Reunion Neuroscience?
Reunion Neuroscience's top competitors include Alto Neuroscience, Supernus Pharmaceuticals and Newron Pharmaceuticals.
What products or services does Reunion Neuroscience offer?
Reunion Neuroscience offers RE104 and RE200s.
Who are Reunion Neuroscience's investors?
Reunion Neuroscience has 8 investors. Key investors include Novo Holdings, Arkin Holdings, Mitsui Global Investment, Plaisance Capital, and FemHealth Ventures.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.